azacitidine + romidepsin + durvalumab + lenalidomide

A combination therapy consisting of **azacitidine**, **romidepsin**, **durvalumab**, and **lenalidomide**, investigated for the treatment of hematological malignancies, particularly T-cell lymphomas and potentially multiple myeloma. Azacitidine is a DNA methyltransferase inhibitor (a hypomethylating agent) that promotes DNA demethylation; romidepsin is a histone deacetylase inhibitor, both functioning as epigenetic modulators. Durvalumab is a monoclonal antibody acting as an immune checkpoint inhibitor targeting PD-L1, enhancing T-cell mediated anti-tumor immune responses. Lenalidomide is an immunomodulatory agent with anti-angiogenic, antineoplastic, and immune-stimulating properties, primarily acting through modulation of the cereblon E3 ubiquitin ligase complex. This combination aims to leverage epigenetic modulation and immune activation for synergistic antitumor effects in refractory or relapsed lymphomas and other hematologic malignancies[1][2][3][5][6][7][10].